BioSpace News Archive

Data analysis leveraging Cheetah Medical technology presented at International Symposium on Intensive Care and Emergency Medicine (ISICEM)

Aurinia Pharmaceuticals Inc. reported its financial results for the fourth quarter and year ended December 31, 2018.

Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that 3,250,000 shares in Partner Company, Motif Bio have been sold (“Sale”) in partial repayment of the loan facility (the “Facility”) originally announced on 5 June 2014 and most recently amended as announced on 11 March 2019 (“Amendment Agreement”).

Nevro Corp. (NYSE: NVRO) (“Nevro”), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman has been appointed President and Chief Executive Officer of Nevro and a member of the Board of Directors (the “Board”), effective today.

ACD/Labs, an informatics company that is celebrating 25 years of providing analytical and chemical knowledge management solutions for R&D, today announced the launch of a new web-based application in support of high throughput (HT) experimentation

The drug delivery and healthcare packaging industry is set for significant growth in 2019 as Pharmapack Europe (#pharmapackeu) – a key bellwether of industry health – welcomed a record 410 exhibiting companies and nearly 5,500 attendees from 75 countries

CloudLIMS, a leading laboratory data management informatics provider, announces the release of a Kits module for its Laboratory Information Management System (LIMS), CloudLIMS.

Oncimmune Holdings plc (AIM:ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces it has acquired Protagen Diagnostics AG (“Protagen”) for a total consideration of up to £4.11 million, to be paid by the allotment of up to 2,635,910 Oncimmune Ordinary Shares at 156p per share, a premium of 71% to the closing mid-market price on 18 March 2019.

My Gene Counsel, a digital health company that provides personalized, easy-to-understand genetic testing reports, today announced a partnership with Ambry Genetics to offer the first One-Stop Solution for direct-to-consumer (DTC) genetic test results confirmed through medical-grade testing.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today the appointment of Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs.